The role of duloxetine in the treatment of anxiety disorders

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 929-935

  De Berardis, Domenico ^a,b   Serroni, Nicola ^b   Carano, Alessandro ^a,c   Scali, Marco ^a,c   Valchera, Alessandro ^d   Campanella, Daniela ^a,b   D'Albenzio, Alessandro ^a   Di Giuseppe, Berardo ^b   Moschetta, Francesco Saverio ^b   Salerno, Rosa Maria ^a   Ferro, Filippo Maria ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SPDC   (Italy)

^c Department of Mental Health   (Italy)

^d S Giuseppe Clinic   (Italy)

Author keywords

Anxiety disorders; Duloxetine; Efficacy; Noradrenaline; Serotonin; Tolerability

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DULOXETINE; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FATIGUE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; REVIEW; SOCIAL PHOBIA; SOMNOLENCE; STRESS INCONTINENCE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 56849086723     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s2546     Document Type: Review

References (63)

1. Allgulander C, Hartford J, Russell J, et al. 2007. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin, 23:1245-52.
2. Baldwin DS, Evans DL, Hirschfeld RM, et al. 2002. Can we distinguish anxiety from depression? Psychopharmacol Bull, 36:158-65.
3. Bandelow VB, Wolff-Menzler C, Wedekind D, et al. 2006. Anxiety disorders: long-term treatment and replapse prevention. MMW Fortschr Med, 148:31-4.
4. Bremner JD, Krystal JH, Southwick SM, et al. 1996. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse, 23:39-51.
5. Bymaster FP, Beedle EE, Findlay J, et al. 2003. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett, 13:4477-80.
6. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. 2001. Compare the affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25:871-80.
7. Crippa JA, Filho AS, Freitas MC, et al. 2007. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol, 27:310.
8. Crippa JA, Zuardi AW. 2006. Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol, 9:633-4.
9. Dell'osso B, Mundo E, Marazziti D, et al. 2008. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol, 22:210-13.
10. Deneys ML, Ahearn EP. 2006. Exacerbation of PTSD symptoms with use of duloxetine. J Clin Psychiatry, 67:496-7.
11. Detke MJ, Lu Y, Goldstein DJ, et al. 2002. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo controlled trial. J Clin Psychiatry, 63:308-15.
12. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. 2003. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety, 18:53-61.
13. Endicott J, Russell JM, Raskin J, et al. 2007. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry, 68:518-24.
14. Engleman ES, Perry KW, Mayle DA, et al. 1995. Simultaneous increases of extracellular monoamines in microdyalisates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology, 12:287-95.
15. Fava M, Martinez JM, Greist J, et al. 2007. The efficacy and tolerability of duloxetine in the treatment of anxious versus nonanxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry, 19:187-95.
16. Frampton JE, Plosker GL. 2007. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs, 21:581-609.
17. Fuller RW, Hemrick-Luecke SK, Snoddy HD. 1994. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther, 269:132-6.
18. Gambi F, De Berardis D, Campanella D, et al. 2005. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol, 19:483-7.
19. Goodman WK. 2004. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry, 65:8-13.
20. Graeff FG, Viana MB, Mora PO. 1997. Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev, 21:791-9.
21. Greenberg PE, Sisitsky T, Kessler RC, et al. 1999. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry, 60:427-35.
22. Hanretta AT, Malek-Ahmadi P. 2007. Combined Use of ECT with Duloxetine and Olanzapine: A Case Report, J ECT, 22:139-41.
23. Hariri AR, Mattay VS, Tessitore A, et al. 2002. Serotonin transporter genetic variation and the response of the human amygdala. Science, 297:400-3.
24. Hartford J, Kornstein S, Liebowitz M, et al. 2007. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol, 22:167-74.
25. Iny LJ, Pecknold J, Suranyi-Cadotte BE, et al. 1994. Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry, 36:281-91.
26. Kasamo K, Blier P, de Montigny C. 1996. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: In vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther, 277:278-86.
27. Kessler RC, Chiu WT, Demler O, et al. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:617-27.
28. Kihara T, Ikeda M. 1995. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther, 272:177-83.
29. Koponen H, Allgulander C, Erickson J, et al. 2007. Efficacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary care physicians. Prim Care Companion J Clin Psychiatry, 9:100-7.
30. Lesch KP, Bengel D, Heils A, et al. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274:1527-31.
31. Lewis-Fernandez R, Blanco C, Mallinckrodt CH, et al. 2006. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. J Clin Psychiatry, 67:1379-90.
32. Luis Blay S, Black DW. 2007. A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry, 9:234-5.
33. Mirza NR, Nielsen EØ, Troelsen KB. 2007. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry, 31:858-66.
34. Moore K. 2004. Duloxetine: a new approach for treating stress urinary incontinence? Int J Gynecol Obstet, 86:53-62.
35. Morilak DA, Barrera G, Echevarria DJ, et al. 2005. Role of brain norepinephrine in the behavioral response to stress. Prog Neuropsychopharmacol Biol Psychiatry, 29:1214-24.
36. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. 2002. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull, 36:106-32.
37. Nutt DJ, Stein DJ. 2006. Understanding the neurobiology of comorbidity in anxiety disorders. CNS Spear, 11:3-20.
38. Ohara K, Suzuki Y, Ochiai M, et al. 1999. A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry, 23:55-65.
39. Pitsikas N. 2000. Duloxetine Eli Lilly and Co. Curr Gpin Investig Drugs, 1:116-21.
40. Pollack MH. 2001. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry, 62:20-5.
41. Pollack MH, Endicott J, Liebowitz M, et al. 2008. Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. J Psychiatr Res, Jan 24 [Epub ahead of print].
42. Rickels K, Pollack MH, Sheehan DV, et al. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry, 157:968-74.
43. Rickels K, Pollack MH, Feltner DE, et al. 2005. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry, 62:1022-30.
44. Rynn MA, Brawman-Mintzer O. 2004. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr, 9:716-23.
45. Rynn M, Russell J, Erickson J, et al. 2008. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety, 25:182-9.
46. Russell JM, Weisberg R, Fava M, et al. 2007. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety, Jun 22 [Epub ahead of print].
47. Sharma A, Goldberg MJ, Cerimele BJ. 2000. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol, 40:161-7.
48. Shearer SL. 2007. Recent advances in the understanding and treatment of anxiety disorders. Prim Care, 34:475-504.
49. Sheehan DV, Sheehan KH. 2007. Current approaches to the pharmacologic treatment of anxiety disorders. Psychopharmacol Bull, 40:98-109.
50. Shelton RC, Andorn AC, Mallinckrodt CH, et al. 2007. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol, 22:348-55.
51. Stahl SM, Grady MM, Moret C, et al. 2005. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr, 10:732-47.
52. Troelsen KB, Nielsen EO, Mirza NR. 2005. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology, 181:741-50.
53. Van Bockstaele EJ. 2000. Multiple substrates for serotonergic modulation of rat locus coeruleus neurons and relationships with kainate receptors. Brain Res Bull, 51:433-42.
54. Vaswani M, Linda FK, Ramesh S. 2003. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry, 27:85-102.
55. Wernicke JF, Pritchett YL, D'Souza DN, et al. 2006. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 67:1411-20.
56. Westanmo AD, Gayken J, Haight R. 2005. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Heallh Syst Pharm, 62:2481-90.
57. Westenberg HG, Sandner C. 2006. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract, 60:482-91.
58. Williams VSL, Baldwin DS, Hogue SL, et al. 2006. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry, 67:204-10.
59. Wang PS, Lane M, Olfson M, et al. 2005. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:629-40.
60. Wong DT. 1998. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Investig Drugs, 7:1-9.
61. Wong DT, Bymaster FP. 2002, Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res, 58:169-222.
62. Wong DT, Bymaster FP, Mayle DA, et al. 1993. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology, 8:23-33.
63. Wrase J, Reimold M, Puls I, et al. 2006. Serotonergic dysfunction: brain Imaging and behavioral correlates. Cogn Affect Behav Neurosci, 6:53-61.